Trial reportEuropean journal of nuclear medicine and molecular imaging2026
Prospective pilot study with [
Trial report in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04758780 (Prospective Phase II Pilot Study, Assessing Imaging Performance of 89Zirconium-labelled Girentuximab), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Phase II Pilot Study, Assessing Imaging Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT (Positron Emission Tomography/Computerized Tomography) in Metastatic Triple Negative Breast Cancer Patients
Who cites it
1 citing paper in PubMed.
- Noninvasive molecular imaging signatures of histopathological growth patterns in colorectal cancer liver metastases.Clinical & experimental metastasis · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purpose of the reportMetastatic triple negative breast cancer (mTNBC) is aggressive with drug-resistance. Evaluating new markers is an unmet need. Anhydrase carbonic-IX (CA-IX), a hypoxia-mediated breast tumor growth regulator, is important for maintaining BC stem cells within a hypoxic region. This pilot prospective study "OPALESCENCE" assessed [ MATERIALS AND
methodsPatients underwent FDG and TLX250-CDx PET/CT and conventional imaging (CI) if needed. Intravenous administration of 37±10% MBq TLX250-CDx was performed, The PET/CT was acquired at Day 3 or 5 post injection. Gold standard composite was based on FDG PET/CT, CI and follow-up. Tumor standard uptake values (SUV
resultsTwelve mTNBC patients were included. Of 273 lesions confirmed with the gold standard, 231 were detected by TLX250-CDx and 264 by FDG PET/CT. Overall sensitivity of TLX250-CDx PET/CT was 87.5% with 100% sensitivity for breast, skin, and adrenal gland, and 88.0% and 91.9% for node and bone lesions respectively. In contrast to FDG PET/CT, TLX250-CDx PET/CT revealed brain metastases. Tumor burden evaluated with TTV was equivalent between both PET/CT methods. For 7/12 patients, IHC analyses showed CA-IX expression lesions from 100% to 10% with an intensity from 3+ to 2+. No safety issue was reported after TLX250-CDx injection.
conclusion[ THE TRIAL REGISTRY: Clinical trial.gov, the unique identifying number: NCT04758780, date of registration: 16/02/2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.